XML 49 R32.htm IDEA: XBRL DOCUMENT v3.25.0.1
Licenses, Asset Acquisitions and Contingent Consideration (Tables)
 12 Months Ended
Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Schedule of IPR&D Expense
The Company recorded the following IPR&D expense on the consolidated statements of operations and comprehensive loss (in thousands):
Year Ended December 31,
202420232022
Seralutinib$— $10,000 $— 
Terminated programs— — 65 
Total in process research and development$— $10,000 $65